Results 61 to 70 of about 581 (153)

Present and Future of Central Disorders of Hypersomnolence

Journal of Sleep Research, Volume 34, Issue 5, October 2025.
ABSTRACT Central disorders of hypersomnolence (CDH) are rare neurological conditions lumped by excessive daytime sleepiness (EDS) as primary complaint mostly arising at young age, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and Kleine‐Levin syndrome (KLS). Advances in clinical and translational research have
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial [PDF]

, 2020
Background: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, improved wakefulness and reduced excessive daytime sleepiness (EDS) in studies of participants with narcolepsy with and without cataplexy.
Mayer, G., Mayer G., Dauvilliers, Yves, Shapiro, Colin, Thorpy M. J., Thorpy, M.J., Black, Jed, Dauvilliers, Y., Emsellem, H., Thorpy, Michael, Shapiro, C., Carter, L.P., Lee, L., Mayer, Geert, Lammers, Gert Jan, Plazzi G., Plazzi, G., Lee, Lawrence, Black J., Chen, Dan, Dauvilliers Y., Shapiro C., Chen D., Lammers G. J., Plazzi, Giuseppe, Emsellem H., Carter L. P., Lammers, G.J., Carter, Lawrence, Emsellem, Helene, Lee L., Chen, D., Black, J.   +32 more
core   +1 more source

Effects of Solriamfetol on Quality of Life Measures From a 12-Week Phase 3 Randomized Trial

, 2020
RATIONALE: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. OBJECTIVE: To assess solriamfetol, a dopamine/norepinephrine reuptake inhibitor, treatment effects on daily functioning ...
Maynard, James, Bogan, Richard K, Andry, James M, Carter, Lawrence P, Chen, Dan, Thein, Stephen G, Weaver, Terri E, Stern, Thomas, Benes, Heike, Hudson, John D, Black, Jed, Drake, Christopher L, Bron, Morgan, Lee, Lawrence   +13 more
core   +1 more source

Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes

Pharmaceuticals
Background: Obstructive sleep apnea (OSA) remains under-treated because continuous positive airway pressure, though efficacious, is frequently limited by poor tolerance and adherence.
Jayoung Oh, Ji Ho Choi
doaj   +1 more source

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1743-1753, June 2025.
Drug dose appropriateness is one of the most discussed issues in regulatory reviews. We analyzed dose determinations during Food and Drug Administration (FDA) drug reviews to determine whether there were changes between the proposed and approved doses of new molecular entities (NMEs), including cases where postmarketing dose‐finding studies were ...
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Treating narcolepsy‐related nightmares with cognitive behavioural therapy and targeted lucidity reactivation: A pilot study

Journal of Sleep Research, Volume 34, Issue 3, June 2025.
Cognitive Behavioural Therapy for Nightmares, alone or in combination with targeted lucidity reactivation, significantly reduced nightmare frequency and severity, leading to remission of nightmare disorder in four of six participants. Sleep talking, NREM parasomnia symptoms, and self‐efficacy for managing symptoms also improved significantly.
Jennifer M. Mundt, Kristi E. Pruiksma, Karen R. Konkoly, Clair Casiello‐Robbins, Michael R. Nadorff, Rachel‐Clair Franklin, Sunaina Karanth, Nina Byskosh, Daniel J. Morris, S. Gabriela Torres‐Platas, Remington Mallett, Kiran Maski, Ken A. Paller   +12 more
wiley   +1 more source

The electroretinography to identify biomarkers of idiopathic hypersomnia and narcolepsy type 1

Journal of Sleep Research, Volume 34, Issue 1, February 2025.
Summary Hypersomnia spectrum disorders are underdiagnosed and poorly treated due to their heterogeneity and absence of biomarkers. The electroretinography has been proposed as a proxy of central dysfunction and has proved to be valuable to differentiate certain psychiatric disorders.
Héloïse Rach, Ulker Kilic‐Huck, Pierre A. Geoffroy, Tristan Bourcier, Sophie Braun, Henri Comtet, Elisabeth Ruppert, Laurence Hugueny, Marc Hebert, Eve Reynaud, Patrice Bourgin   +10 more
wiley   +1 more source

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety

Pharmacology Research &Perspectives, Volume 12, Issue 1, February 2024.
Flow diagram of data collection and analysis of pitolisant‐associated adverse events. Abstract Pitolisant, a novel histamine H3‐receptor antagonist, holds significant promise for treating narcolepsy. However, a petition, which highlighted that pitolisant was associated with deaths during clinical trials, has propelled it into the spotlight of ...
Cheng Jiang, Jiancheng Qian, Xin Jiang, Shuohan Zhang, Junxian Zheng, Hongwei Wang   +5 more
wiley   +1 more source

Annual banned‐substance review 16th edition—Analytical approaches in human sports drug testing 2022/2023

Drug Testing and Analysis, Volume 16, Issue 1, Page 5-29, January 2024.
Abstract In this 16th edition of the annual banned‐substance review on analytical approaches in human sports drug testing, literature on recent developments in this particular section of global anti‐doping efforts that was published between October 2022 and September 2023 is summarized and discussed.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

SURWEY real-world study of solriamfetol: initiation, titration, safety, efficacy, and follow-up experience for patients with obstructive sleep apnea in Germany [PDF]

Purpose Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies
Kallweit, Ulf, Mayer, Geert, Burghaus, Lothar, Benes, Heike, Parks, Gregory S., Winter, Yaroslav, Floam, Samantha   +6 more
core   +1 more source